API Gallery
The Metoprolol market is projected to expand at a CAGR of 5.2% between 2025 and 2035, underpinned by its widespread use in cardiovascular disease management. As a selective beta-1 blocker, Metoprolol is commonly prescribed for hypertension, angina pectoris, heart failure, and arrhythmias.
The Canagliflozin market is projected to grow at a CAGR of 6.4% over the forecast period. The growing incidence of Type 2 diabetes and its related comorbidities is driving the market. By encouraging the excretion of glucose through urine, canagliflozin, an inhibitor of the sodium-glucose co-transporter-2 (SGLT2), lowers blood glucose levels.
The Candesartan Cilexetil market is expected to grow at a CAGR of 5.5% over the forecast period. The market is driven by the increasing incidence of hypertension, heart failure, and chronic kidney disease (CKD). Candesartan cilexetil is a prodrug of Candesartan, an angiotensin II receptor blocker (ARB) that effectively lowers blood pressure and reduces cardiovascular risks.
The Ozenoxacin market is projected to expand at a CAGR of 6.9% between 2025 and 2035, driven by increasing awareness and diagnosis of impetigo and superficial skin infections, particularly among pediatric populations.
The Candesartan market is projected to grow at a CAGR of 5.2% over the forecast period. The rising incidence of cardiovascular disorders and hypertension globally was the main factor propelling the market. An angiotensin II receptor blocker (ARB), candesartan lowers the risk of stroke, heart attack, and renal problems while treating high blood pressure and heart failure.
Throughout the projection period, the market for cannabidiol (CBD) is anticipated to rise at a compound annual growth rate (CAGR) of 18.2% due to rising consumer awareness, legalization trends, and growing medicinal uses. CBD, a non-psychoactive substance made from hemp and cannabis, is becoming increasingly popular because of its possible health advantages, which include anti-inflammatory, pain-relieving, anxiety-reducing, and neuroprotective qualities.
The Paclitaxel market is expected to grow at a CAGR of 6.4% from 2025 to 2035, driven by rising global cancer incidence and expanding indications for chemotherapy involving taxane-based regimens.
The market for cannabigerol (CBG) is anticipated to expand at a compound annual growth rate (CAGR) of 16.8% during the forecast period due to growing interest in uncommon cannabinoids and their possible medical uses.
The market for cannabinol (CBN) is anticipated to expand at a compound annual growth rate (CAGR) of 15.9% during the forecast period due to the rising demand for wellness products, therapeutic cannabinoids, and natural sleep aids. Because of its calming, anti-inflammatory, antibacterial, and neuroprotective qualities, CBN—a moderately psychoactive cannabinoid produced by the breakdown of THC—has drawn interest.
The Pacritinib market is expected to expand at a CAGR of 7.2% from 2025 to 2035, driven by the growing incidence of hematologic cancers and increasing demand for targeted therapies with favorable safety profiles.
The market for canrenoate potassium is anticipated to expand at a compound annual growth rate (CAGR) of 5.6% during the forecast period due to its growing application in the management of heart failure, hypertension, and fluid retention (edema).
The market for cantharidin is anticipated to expand at a compound annual growth rate (CAGR) of 6.4% during the forecast period due to its growing use in cancer research, dermatology, and wart removal procedures. Because it can cause controlled epidermal blistering without leaving scars, cantharidin, a vesicant produced from blister beetles, has been utilized in topical therapies for warts and molluscum contagiosum.
The market for capecitabine is anticipated to expand at a compound annual growth rate (CAGR) of 5.9% during the forecast period due to its growing use as a first-line chemotherapy drug for the treatment of breast and colorectal cancer. The oral prodrug of 5-fluorouracil (5-FU), capecitabine, is frequently given because of its easy administration, low hospitalization requirements, and potent tumor-targeting capabilities.
The market for capivasertib is anticipated to expand at a compound annual growth rate (CAGR) of 7.2% during the projected period due to its potential use as an AKT inhibitor in targeted cancer treatments. The effectiveness of capivasertib in treating prostate and breast cancer, especially in patients with mutations in the PI3K/AKT pathway, is being extensively researched.
Capmatinib’s growing use in treating non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation is expected to propel the market’s growth at a compound annual growth rate (CAGR) of 6.8% over the forecast period. A strong and specific MET inhibitor, capmatinib, has shown remarkable effectiveness in targeted cancer treatment, especially for patients with advanced or metastatic non-small cell lung cancer.
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
